|
1
|
Efstratiadis A: Genetics of mouse growth.
Int J Dev Biol. 42:955–976. 1998.PubMed/NCBI
|
|
2
|
Eggenschwiler J, Ludwig T, Fisher P,
Leighton PA, Tilghman SM and Efstratiadis A: Mouse mutant embryos
overexpressing IGF-II exhibit phenotypic features of the
beckwith-wiedemann and simpson-golabi-behmel syndromes. Genes Dev.
11:3128–3142. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
St-Pierre J, Hivert MF, Perron P, Poirier
P, Guay SP, Brisson D and Bouchard L: IGF2 DNA methylation is a
modulator of newborn's fetal growth and development. Epigenetics.
7:1125–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoyo C, Fortner K, Murtha AP, Schildkraut
JM, Soubry A, Demark-Wahnefried W, Jirtle RL, Kurtzberg J, Forman
MR, Overcash F, et al: Association of cord blood methylation
fractions at imprinted insulin-like growth factor 2 (IGF2), plasma
IGF2, and birth weight. Cancer Causes Control. 23:635–645.
2012.PubMed/NCBI
|
|
5
|
Chin E and Bondy C: Insulin-like growth
factor system gene expression in the human kidney. J Clin
Endocrinol Metab. 75:962–968. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sferruzzi-Perri AN, Sandovici I,
Constancia M and Fowden AL: Placental phenotype and the
insulin-like growth factors: Resource allocation to fetal growth. J
Physiol. 595:5057–5093. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuang X: Study of the relationship between
WT1 and IGF2 DNA methylation and kidney development and function in
intrauterine growth retardation rat. PhD dissertation (Shanghai).
Fudan University. 2012.(In Chinese).
|
|
8
|
Du L, Lin L, Li Q, Liu K, Huang Y, Wang X,
Cao K, Chen X, Cao W, Li F, et al: IGF-2 preprograms maturing
macrophages to acquire oxidative phosphorylation-dependent
anti-inflammatory properties. Cell Metab. 29:1363–1375.e8. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livingstone C and Borai A: Insulin-like
growth factor-II: Its role in metabolic and endocrine disease. Clin
Endocrinol (Oxf). 80:773–781. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsumoto T, Kinoshita E, Maeda H, Niikawa
N, Kurosaki N, Harada N, Yun K, Sawai T, Aoki S, Kondoh T, et al:
Molecular analysis of a patient with beckwith-wiedemann syndrome,
rhabdomyosarcoma and renal cell carcinoma. Jpn J Hum Genet.
39:225–234. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
LeRoith D, Werner H, Beitner-Johnson D and
Roberts CT Jr: Molecular and cellular aspects of the insulin-like
growth factor I receptor. Endocr Rev. 16:143–163. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baserga R, Hongo A, Rubini M, Prisco M and
Valentinis B: The IGF-I receptor in cell growth, transformation and
apoptosis. Biochim Biophys Acta. 1332:F105–F126. 1997.PubMed/NCBI
|
|
13
|
Burvin R, LeRoith D, Harel H, Zloczower M,
Marbach M and Karnieli E: The effect of acute insulin-like growth
factor-II administration on glucose metabolism in the rat. Growth
Horm IGF Res. 8:205–210. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Salmon WD Jr and Daughaday WH: A
hormonally controlled serum factor which stimulates sulfate
incorporation by cartilage in vitro. J Lab Clin Med. 49:825–836.
1957.PubMed/NCBI
|
|
15
|
Engström W, Shokrai A, Otte K, Granérus M,
Gessbo A, Bierke P, Madej A, Sjölund M and Ward A: Transcriptional
regulation and biological significance of the insulin like growth
factor II gene. Cell Prolif. 31:173–189. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vu TH and Hoffman AR: Promoter-specific
imprinting of the human insulin-like growth factor-II gene. Nature.
371:714–717. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Belfiore A, Malaguarnera R, Vella V,
Lawrence MC, Sciacca L, Frasca F, Morrione A and Vigneri R: Insulin
receptor isoforms in physiology and disease: An updated view.
Endocr Rev. 38:379–431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Constância M, Hemberger M, Hughes J, Dean
W, Ferguson-Smith A, Fundele R, Stewart F, Kelsey G, Fowden A,
Sibley C and Reik W: Placental-specific IGF-II is a major modulator
of placental and fetal growth. Nature. 417:945–948. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chao W and D'Amore PA: IGF2: Epigenetic
regulation and role in development and disease. Cytokine Growth
Factor Rev. 19:111–120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Issa JP, Vertino PM, Boehm CD, Newsham IF
and Baylin SB: Switch from monoallelic to biallelic human IGF2
promoter methylation during aging and carcinogenesis. Proc Natl
Acad Sci USA. 93:11757–11762. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhan S, Shapiro D, Zhan S, Zhang L,
Hirschfeld S, Elassal J and Helman LJ: Concordant loss of
imprinting of the human insulin-like growth factor II gene
promoters in cancer. J Biol Chem. 270:27983–27986. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Dijk MA, van Schaik FM, Bootsma HJ,
Holthuizen P and Sussenbach JS: Initial characterization of the
four promoters of the human insulin-like growth factor II gene. Mol
Cell Endocrinol. 81:81–94. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Huang S, Tian N, Xu Q, Zhan X,
Peng F, Wang X, Su N, Feng X, Tang X, et al: Association of the
remnant cholesterol to high-density lipoprotein cholesterol ratio
with mortality in peritoneal dialysis patients. Lipids Health Dis.
24:1072025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morali OG, Jouneau A, McLaughlin KJ,
Thiery JP and Larue L: IGF-II promotes mesoderm formation. Dev
Biol. 227:133–145. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pardo M, Cheng Y, Sitbon YH, Lowell JA,
Grieco SF, Worthen RJ, Desse S and Barreda-Diaz A: Insulin growth
factor 2 (IGF2) as an emergent target in psychiatric and
neurological disorders. Review. Neurosci Res. 149:1–13. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baserga R: The IGF-I receptor in cancer
research. Exp Cell Res. 253:1–6. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wojtalla A, Salm F, Christiansen DG,
Cremona T, Cwiek P, Shalaby T, Gross N, Grotzer MA and Arcaro A:
Novel agents targeting the IGF-1R/PI3K pathway impair cell
proliferation and survival in subsets of medulloblastoma and
neuroblastoma. PLoS One. 7:e471092012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vigneri PG, Tirrò E, Pennisi MS, Massimino
M, Stella S, Romano C and Manzella L: The insulin/IGF system in
colorectal cancer development and resistance to therapy. Front
Oncol. 5:2302015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vella V, Pandini G, Sciacca L, Mineo R,
Vigneri R, Pezzino V and Belfiore A: A novel autocrine loop
involving IGF-II and the insulin receptor isoform-A stimulates
growth of thyroid cancer. J Clin Endocrinol Metab. 87:245–254.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Belfiore A, Frasca F, Pandini G, Sciacca L
and Vigneri R: Insulin receptor isoforms and insulin
receptor/insulin-like growth factor receptor hybrids in physiology
and disease. Endocr Rev. 30:586–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Andersen M, Nørgaard-Pedersen D, Brandt J,
Pettersson I and Slaaby R: IGF1 and IGF2 specificities to the two
insulin receptor isoforms are determined by insulin receptor amino
acid 718. PLoS One. 12:e01788852017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Louvi A, Accili D and Efstratiadis A:
Growth-promoting interaction of IGF-II with the insulin receptor
during mouse embryonic development. Dev Biol. 189:33–48. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fukuda I, Hizuka N, Ishikawa Y, Yasumoto
K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y and Takano K:
Clinical features of insulin-like growth factor-II producing
non-islet-cell tumor hypoglycemia. Growth Horm IGF Res. 16:211–216.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khowaja A, Johnson-Rabbett B, Bantle J and
Moheet A: Hypoglycemia mediated by paraneoplastic production of
insulin like growth factor-2 from a malignant renal solitary
fibrous tumor-clinical case and literature review. BMC Endocr
Disord. 14:492014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rikhof B, Van Den Berg G and Van Der Graaf
WTA: Non-islet cell tumour hypoglycaemia in a patient with a
gastrointestinal stromal tumour. Acta Oncol. 44:764–766. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zapf J: Role of insulin-like growth factor
II and IGF binding proteins in extrapancreatic tumor hypoglycemia.
Horm Res. 42:20–26. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zapf J, Futo E, Peter M and Froesch ER:
Can ‘big’ insulin-like growth factor II in serum of tumor patients
account for the development of extrapancreatic tumor hypoglycemia?
J Clin Invest. 90:2574–2584. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dynkevich Y, Rother KI, Whitford I,
Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N,
Shanik MH, et al: Tumors, IGF-2, and hypoglycemia: insights from
the clinic, the laboratory, and the historical archive. Endocr Rev.
34:798–826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu XH, Wang LH, Song JF, Wang WP and Shan
BE: Effect of IGF-II stimulation on the expression of matrix
metalloproteinase-9 in human ovarian cancer cell line SKOV3. Prog
Obstet Gynecol. 12:413–415. 2003.(In Chinese).
|
|
40
|
Han Y, Cui J, Tao J, Guo L, Guo P, Sun M,
Kang J, Zhang X, Yan C and Li S: CREG inhibits migration of human
vascular smooth muscle cells by mediating IGF-II endocytosis. Exp
Cell Res. 315:3301–3311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhu M, Zhuang J, Li Z, Liu Q, Zhao R, Gao
Z, Midgley AC, Qi T, Tian J, Zhang Z, et al:
Machine-learning-assisted single-vessel analysis of nanoparticle
permeability in tumour vasculatures. Nat Nanotechnol. 18:657–666.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou L, Liu Y, Xu T, Dong L, Yang X and
Wang C: Malignant solitary fibrous tumor of the kidney with IGF2
secretion and without hypoglycemia. World J Surg Oncol. 22:1792024.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sciacca L, Prisco M, Wu A, Belfiore A,
Vigneri R and Baserga R: Signaling differences from the A and B
isoforms of the insulin receptor (IR) in 32D cells in the presence
or absence of IR substrate-1. Endocrinology. 144:2650–2658. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Escribano O, Gómez-Hernández A,
Díaz-Castroverde S, Nevado C, García G, Otero YF, Perdomo L, Beneit
N and Benito M: Insulin receptor isoform A confers a higher
proliferative capability to pancreatic beta cells enabling glucose
availability and IGF-I signaling. Mol Cell Endocrinol. 409:82–91.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ghosh P, Dahms NM and Kornfeld S: Mannose
6-phosphate receptors: New twists in the tale. Nat Rev Mol Cell
Biol. 4:202–212. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
El-Shewy HM and Luttrell LM: Insulin-like
growth factor-2/mannose-6 phosphate receptors. Vitam Horm.
80:667–697. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Y, MacDonald RG, Thinakaran G and Kar
S: Insulin-like growth factor-II/cation-independent mannose
6-phosphate receptor in neurodegenerative diseases. Mol Neurobiol.
54:2636–2658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nadimpalli SK and Amancha PK: Evolution of
mannose 6-phosphate receptors (MPR300 and 46): Lysosomal enzyme
sorting proteins. Curr Protein Pept Sci. 11:68–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Massagué J: The transforming growth
factor-beta family. Annu Rev Cell Biol. 6:597–641. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Leksa V, Godar S, Schiller HB, Fuertbauer
E, Muhammad A, Slezakova K, Horejsi V, Steinlein P, Weidle UH,
Binder BR and Stockinger H: TGF-beta-induced apoptosis in
endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J
Cell Sci. 118:4577–4586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Livingstone C: IGF2 and cancer. Endocr
Relat Cancer. 20:R321–R339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sélénou C, Brioude F, Giabicani E, Sobrier
ML and Netchine I: IGF2: Development, genetic and epigenetic
abnormalities. Cells. 11:18862022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhu Y, Chen L and Song B, Cui Z, Chen G,
Yu Z and Song B: Insulin-like growth factor-2 (IGF-2) in fibrosis.
Biomolecules. 12:15572022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wolf E, Hoeflich A and Lahm H: What is the
function of IGF-II in postnatal life? Answers from transgenic mouse
models. Growth Horm IGF Res. 8:185–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Barroca V, Lewandowski D, Jaracz-Ros A and
Hardouin SN: Paternal insulin-like growth factor 2 (Igf2) regulates
stem cell activity during adulthood. eBioMedicine. 15:150–162.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang MJ, Chen F, Liu QG, Liu CC, Yao H, Yu
B, Zhang HB, Yan HX, Ye Y, Chen T, et al: Insulin-like growth
factor 2 is a key mitogen driving liver repopulation in mice. Cell
Death Dis. 9:262018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wolf E, Kramer R, Blum WF, Föll J and Brem
G: Consequences of postnatally elevated insulin-like growth
factor-II in transgenic mice: Endocrine changes and effects on body
and organ growth. Endocrinology. 135:1877–1886. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Blackburn A, Schmitt A, Schmidt P, Wanke
R, Hermanns W, Brem G and Wolf E: Actions and interactions of
growth hormone and insulin-like growth factor-II: Body and organ
growth of transgenic mice. Transgenic Res. 6:213–222. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Avner ED and Sweeney WE Jr: Polypeptide
growth factors in metanephric growth and segmental nephron
differentiation. Pediatr Nephrol. 4:372–377. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jelinic P and Shaw P: Loss of imprinting
and cancer. J Pathol. 211:261–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sun FL, Dean WL, Kelsey G, Allen ND and
Reik W: Transactivation of Igf2 in a mouse model of
beckwith-wiedemann syndrome. Nature. 389:809–815. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lui JC, Finkielstain GP, Barnes KM and
Baron J: An imprinted gene network that controls mammalian somatic
growth is down-regulated during postnatal growth deceleration in
multiple organs. Am J Physiol Regul Integr Comp Physiol.
295:R189–R196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hirschberg R and Adler S: Insulin-like
growth factor system and the kidney: Physiology, pathophysiology,
and therapeutic implications. Am J Kidney Dis. 31:901–919. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Svensson J, Tivesten A, Sjögren K,
Isaksson O, Bergström G, Mohan S, Mölne J, Isgaard J and Ohlsson C:
Liver-derived IGF-I regulates kidney size, sodium reabsorption, and
renal IGF-II expression. J Endocrinol. 193:359–366. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Feld S and Hirschberg R: Growth hormone,
the insulin-like growth factor system, and the kidney. Endocr Rev.
17:423–480. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Moerth C, Schneider MR, Renner-Mueller I,
Blutke A, Elmlinger MW, Erben RG, Camacho-Hübner C, Hoeflich A and
Wolf E: Postnatally elevated levels of insulin-like growth factor
(IGF)-II fail to rescue the dwarfism of IGF-I-deficient mice except
kidney weight. Endocrinology. 148:441–451. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
LeRoith D, Holly JMP and Forbes BE:
Insulin-like growth factors: Ligands, binding proteins, and
receptors. Mol Metab. 52:1012452021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rabkin R and Schaefer F: New concepts:
Growth hormone, insulin-like growth factor-I and the kidney. Growth
Horm IGF Res. 14:270–276. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kie JH, Kapturczak MH, Traylor A, Agarwal
A and Hill-Kapturczak N: Heme oxygenase-1 deficiency promotes
epithelial-mesenchymal transition and renal fibrosis. J Am Soc
Nephrol. 19:1681–1691. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hale LJ, Welsh GI, Perks CM, Hurcombe JA,
Moore S, Hers I, Saleem MA, Mathieson PW, Murphy AJ, Jeansson M, et
al: Insulin-like growth factor-II is produced by, signals to and is
an important survival factor for the mature podocyte in man and
mouse. J Pathol. 230:95–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Grotendorst GR, Rahmanie H and Duncan MR:
Combinatorial signaling pathways determine fibroblast proliferation
and myofibroblast differentiation. FASEB J. 18:469–479. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Elchebly M, Payette P, Michaliszyn E,
Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J,
Chan CC, et al: Increased insulin sensitivity and obesity
resistance in mice lacking the protein tyrosine phosphatase-1B
gene. Science. 283:1544–1548. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Daza-Arnedo R, Rico-Fontalvo J,
Aroca-Martínez G, Rodríguez-Yanez T, Martínez-Ávila MC,
Almanza-Hurtado A, Cardona-Blanco M, Henao-Velásquez C,
Fernández-Franco J, Unigarro-Palacios M, et al: Insulin and the
kidneys: A contemporary view on the molecular basis. Front Nephrol.
3:11333522023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Singh S, Sharma R, Kumari M and Tiwari S:
Insulin receptors in the kidneys in health and disease. World J
Nephrol. 8:11–22. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Enguita-Germán M and Fortes P: Targeting
the insulin-like growth factor pathway in hepatocellular carcinoma.
World J Hepatol. 6:716–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang X, Lin L, Lan B, Wang Y, Du L, Chen
X, Li Q, Liu K, Hu M, Xue Y, et al: IGF2R-initiated proton
rechanneling dictates an anti-inflammatory property in macrophages.
Sci Adv. 6:eabb73892020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Rainier S, Dobry CJ and Feinberg AP: Loss
of imprinting in hepatoblastoma. Cancer Res. 55:1836–1838.
1995.PubMed/NCBI
|
|
78
|
Honda S, Arai Y, Haruta M, Sasaki F, Ohira
M, Yamaoka H, Horie H, Nakagawara A, Hiyama E, Todo S and Kaneko Y:
Loss of imprinting of IGF2 correlates with hypermethylation of the
H19 differentially methylated region in hepatoblastoma. Br J
Cancer. 99:1891–1899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Bell AC and Felsenfeld G: Methylation of a
CTCF-dependent boundary controls imprinted expression of the Igf2
gene. Nature. 405:482–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Thorvaldsen JL, Duran KL and Bartolomei
MS: Deletion of the H19 differentially methylated domain results in
loss of imprinted expression of H19 and Igf2. Genes Dev.
12:3693–3702. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tremblay KD, Saam JR, Ingram RS, Tilghman
SM and Bartolomei MS: A paternal-specific methylation imprint marks
the alleles of the mouse H19 gene. Nat Genet. 9:407–413. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Chang S and Bartolomei MS: Modeling human
epigenetic disorders in mice: Beckwith-wiedemann syndrome and
silver-russell syndrome. Dis Model Mech. 13:dmm0441232020.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Han L, Lee DH and Szabó PE: CTCF is the
master organizer of domain-wide allele-specific chromatin at the
H19/Igf2 imprinted region. Mol Cell Biol. 28:1124–1135. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Matsuzaki H, Kuramochi D, Okamura E,
Hirakawa K, Ushiki A and Tanimoto K: Recapitulation of gametic DNA
methylation and its post-fertilization maintenance with reassembled
DNA elements at the mouse Igf2/H19 locus. Epigenetics Chromatin.
13:22020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Leighton PA, Saam JR, Ingram RS, Stewart
CL and Tilghman SM: An enhancer deletion affects both H19 and Igf2
expression. Genes Dev. 9:2079–2089. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Neirijnck Y, Papaioannou MD and Nef S: The
insulin/IGF system in mammalian sexual development and
reproduction. Int J Mol Sci. 20:44402019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Huang SCC, Smith AM, Everts B, Colonna M,
Pearce EL, Schilling JD and Pearce EJ: Metabolic reprogramming
mediated by the mTORC2-IRF4 signaling axis is essential for
macrophage alternative activation. Immunity. 45:817–830. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bridgewater DJ, Ho J, Sauro V and Matsell
DG: Insulin-like growth factors inhibit podocyte apoptosis through
the PI3 kinase pathway. Kidney Int. 67:1308–1314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tziastoudi M, Theoharides TC, Nikolaou E,
Efthymiadi M, Eleftheriadis T and Stefanidis I: Key genetic
components of fibrosis in diabetic nephropathy: An updated
systematic review and meta-analysis. Int J Mol Sci. 23:153312022.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Liao J, Song S, Gusscott S, Fu Z,
VanderKolk I, Busscher BM, Lau KH, Brind'Amour J and Szabó PE:
Establishment of paternal methylation imprint at the H19/Igf2
imprinting control region. Sci Adv. 9:eadi20502023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Levey AS and James MT: Acute kidney
injury. Ann Intern Med. 167:ITC66–ITC80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhan Z, Chen J, Zhou H, Hong X, Li L, Qin
X, Fu H and Liu Y: Chronic alcohol consumption aggravates acute
kidney injury through integrin β1/JNK signaling. Redox Biol.
77:1033862024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yamamoto R, Li Q, Otsuki N, Shinzawa M,
Yamaguchi M, Wakasugi M, Nagasawa Y and Isaka Y: A dose-dependent
association between alcohol consumption and incidence of
proteinuria and low glomerular filtration rate: A systematic review
and meta-analysis of cohort studies. Nutrients. 15:15922023.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Orth SR: Smoking and the kidney. J Am Soc
Nephrol. 13:1663–1672. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Chen Q and Ou L: Meta-analysis of the
association between the dietary inflammatory index and risk of
chronic kidney disease. Eur J Clin Nutr. 79:7–14. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Danziger J, Chen KP, Lee J, Feng M, Mark
RG, Celi LA and Mukamal KJ: Obesity, acute kidney injury, and
mortality in critical illness. Crit Care Med. 44:328–334. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Tan X, Tao Q, Yin S, Fu G, Wang C, Xiang
F, Hu H, Zhang S, Wang Z and Li D: A single administration of FGF2
after renal ischemia-reperfusion injury alleviates post-injury
interstitial fibrosis. Nephrol Dial Transplant. 38:2537–2549. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Tsao T, Wang J, Fervenza FC, Vu TH, Jin
IH, Hoffman AR and Rabkin R: Renal growth hormone-insulin-like
growth factor-I system in acute renal failure. Kidney Int.
47:1658–1668. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhang L, Ma X and Wang JQ: Research
progress on the correlation between insulin-like growth factor II,
its binding protein 2 and diabetic nephropathy. Clin Med China.
32:954–957. 2016.(In Chinese).
|
|
100
|
Kashani K, Al-Khafaji A, Ardiles T,
Artigas A, Bagshaw SM, Bell M, Bihorac A, Birkhahn R, Cely CM,
Chawla LS, et al: Discovery and validation of cell cycle arrest
biomarkers in human acute kidney injury. Crit Care. 17:R252013.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Livingston MJ, Shu S, Fan Y, Li Z, Jiao Q,
Yin XM, Venkatachalam MA and Dong Z: Tubular cells produce FGF2 via
autophagy after acute kidney injury leading to fibroblast
activation and renal fibrosis. Autophagy. 19:256–277. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Das S, Thakur S, Korenjak M, Sidorenko VS,
Chung FFL and Zavadil J: Aristolochic acid-associated cancers: A
public health risk in need of global action. Nat Rev Cancer.
22:576–591. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Vanherweghem JL, Depierreux M, Tielemans
C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D,
Verbeelen D, Vanhaelen-Fastre R, et al: Rapidly progressive
interstitial renal fibrosis in young women: Association with
slimming regimen including Chinese herbs. Lancet. 341:387–391.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Lebeau C, Arlt VM, Schmeiser HH, Boom A,
Verroust PJ, Devuyst O and Beauwens R: Aristolochic acid impedes
endocytosis and induces DNA adducts in proximal tubule cells.
Kidney Int. 60:1332–1342. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wen YJ, Qu L and Li XM: Ischemic injury
underlies the pathogenesis of aristolochic acid-induced acute
kidney injury. Transl Res. 152:38–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Komatsu M, Funakoshi T, Aki T and Unuma K:
Aristolochic acid-induced DNA adduct formation triggers acute DNA
damage response in rat kidney proximal tubular cells. Toxicol Lett.
406:1–8. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Chen J, Li H, Bai Y, Luo P, Cheng G, Ding
Z, Xu Z, Gu L, Wong L, Pang X, et al: Spatially resolved
multi-omics unravels region-specific responses, microenvironment
remodeling and metabolic reprogramming in aristolochic acid
nephropathy. Innov Med. 2:1000662024. View Article : Google Scholar
|
|
108
|
Ratnayake D, Nguyen PD, Rossello FJ,
Wimmer VC, Tan JL, Galvis LA, Julier Z, Wood AJ, Boudier T, Isiaku
AI, et al: Macrophages provide a transient muscle stem cell niche
via NAMPT secretion. Nature. 591:281–287. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Li H, Li P, Li S, Zhang X, Dong X and Yang
M: Mechanism of transforming growth factor- β1 induce renal
fibrosis based on transcriptome sequencing analysis. J Zhejiang
Univ (Med Sci). 52:594–604. 2023.(In Chinese). View Article : Google Scholar
|
|
110
|
Chen J, Luo P, Wang C, Yang C, Bai Y, He
X, Zhang Q, Zhang J, Yang J, Wang S and Wang J: Integrated
single-cell transcriptomics and proteomics reveal cellular-specific
responses and microenvironment remodeling in aristolochic acid
nephropathy. JCI Insight. 7:e1573602022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Youl ENH, Husson C, El Khattabi C, El Mere
S, Declèves AE, Pochet S, Nortier J and Antoine MH:
Characterization of cytotoxic effects of aristolochic acids on the
vascular endothelium. Toxicol In Vitro. 65:1048112020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Yamamoto S, Yamamoto M, Nakamura J, Mii A,
Yamamoto S, Takahashi M, Kaneko K, Uchino E, Sato Y, Fukuma S, et
al: Spatiotemporal ATP dynamics during AKI predict renal prognosis.
J Am Soc Nephrol. 31:2855–2869. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Furuhashi M: New insights into purine
metabolism in metabolic diseases: Role of xanthine oxidoreductase
activity. Am J Physiol Endocrinol Metab. 319:E827–E834. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Johnson TA, Jinnah HA and Kamatani N:
Shortage of cellular ATP as a cause of diseases and strategies to
enhance ATP. Front Pharmacol. 10:982019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Dissanayake LV, Zietara A, Levchenko V,
Spires DR, Burgos Angulo M, El-Meanawy A, Geurts AM, Dwinell MR,
Palygin O and Staruschenko A: Lack of xanthine dehydrogenase leads
to a remarkable renal decline in a novel hypouricemic rat model.
iscience. 25:1048872022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Chung HY, Baek BS, Song SH, Kim MS, Huh
JI, Shim KH, Kim KW and Lee KH: Xanthine dehydrogenase/ xanthine
oxidase and oxidative stress. Age (Omaha). 20:127–140. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Dong Y, Chen S, He H, Sun ZR, Jiang LX, Gu
YQ, Zhang Y, Feng F, Chen C, Fan ZC, et al: Skullcapflavone II, a
novel NQO1 inhibitor, alleviates aristolochic acid I-induced liver
and kidney injury in mice. Acta Pharmacol Sin. 44:1429–1441. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Li C, Wang X, Bi Y, Yu H, Wei J and Zhang
Y, Han L and Zhang Y: Potent inhibitors of organic anion
transporters 1 and 3 from natural compounds and their protective
effect on aristolochic acid nephropathy. Toxicol Sci. 175:279–291.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kovesdy CP: Epidemiology of chronic kidney
disease: An update 2022. Kidney Int Suppl (2011). 12:7–11. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Yang DL and Luo NP: Changes of serum TGF-α
and IGF-II levels in patients with chronic renal failure before
receiving homedialysis and their clinical significance. J Pract Med
& Pharm. 22:683–685. 2005.(In Chinese).
|
|
121
|
Lohia S, Latosinska A, Zoidakis J,
Makridakis M, Mischak H, Glorieux G, Vlahou A and Jankowski V:
#4547 Identification of glycosylated igf2 in human urinary
peptidome and its association with CKD. Nephrol Dial Transplant. 38
(Suppl 1):gfad063c_4547. 2023. View Article : Google Scholar
|
|
122
|
Pearce EL and Pearce EJ: Metabolic
pathways in immune cell activation and quiescence. Immunity.
38:633–643. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Kelly B and O'Neill LA: Metabolic
reprogramming in macrophages and dendritic cells in innate
immunity. Cell Res. 25:771–784. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
O'Neill LAJ and Pearce EJ:
Immunometabolism governs dendritic cell and macrophage function. J
Exp Med. 213:15–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Netea MG, Joosten LA, Latz E, Mills KH,
Natoli G, Stunnenberg HG, O'Neill LA and Xavier RJ: Trained
immunity: A program of innate immune memory in health and disease.
Science. 352:aaf10982016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Netea MG and van der Meer JW: Trained
immunity: An ancient way of remembering. Cell Host Microbe.
21:297–300. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Paust S and von Andrian UH: Natural killer
cell memory. Nat Immunol. 12:500–508. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Mihai S, Codrici E, Popescu ID, Enciu AM,
Albulescu L, Necula LG, Mambet C, Anton G and Tanase C:
Inflammation-related mechanisms in chronic kidney disease
prediction, progression, and outcome. J Immunol Res.
2018:21803732018. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng
J, Li Y, Wang X and Zhao L: Inflammatory responses and
inflammation-associated diseases in organs. Oncotarget.
9:7204–7218. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Thomas S and Karalliedde J: Diabetic
kidney disease. Medicine. 50:704–710. 2022. View Article : Google Scholar
|
|
131
|
Nishi S, Ueno M, Hisaki S, Iino N, Iguchi
S, Oyama Y, Imai N, Arakawa M and Gejyo F: Ultrastructural
characteristics of diabetic nephropathy. Med Electron Microsc.
33:65–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Jia PW and Wang AJ: Correlation of IGF-2
and IGFBP-2 with Diabetic Nephropathy Progress Indicators. J
Kunming Med Univ. 36:55–59. 2015.(In Chinese).
|
|
133
|
Kuang J, Yang HZ, Dong H, et al: IGF and
IGFBP and their relationship with nephropathy in type-2 diabetes
mellitus. Chin J Pract Intern Med. 26:433–436. 2006.(In
Chinese).
|
|
134
|
Devanathan N and Kimble-Hill AC:
Systematic survey of the role of IGF in the link between diabetes
and cancer. Indiana Univ J Undergrad Res. 4:17–26. 2018.PubMed/NCBI
|
|
135
|
Pricci F, Pugliese G, Romano G, Romeo G,
Locuratolo N, Pugliese F, Mene P, Galli G, Casini A, Rotella CM and
Di Mario U: Insulin-like growth factors I and II stimulate
extracellular matrix production in human glomerular mesangial
cells. Comparison with transforming growth factor-beta.
Endocrinology. 137:879–885. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Mahimainathan L, Das F, Venkatesan B and
Choudhury GG: Mesangial cell hypertrophy by high glucose is
mediated by downregulation of the tumor suppressor PTEN. Diabetes.
55:2115–2125. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Sireesha M, Sambasivan V, Kumar VK, Radha
S, Raj AY and Qurratulain H: Relevance of insulin-like growth
factor 2 in the etiopathophysiology of diabetic nephropathy:
Possible roles of phosphatase and tensin homolog on chromosome 10
and secreted protein acidic and rich in cysteine as regulators of
repair. J Diabetes. 1:118–124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zhang LM, Wu BB, Mei CL, Fu LL and Wang
WJ: Effects of secreted protein acidic and rich in cysteine peptide
on change of ultra microstructure and extracellular matrix
secretion of human mesangial cells cultured in vitro. Acad J
Sec Mil Med Univ. 28:36–39. 2007.(In Chinese).
|
|
139
|
Bloomgarden ZT: Diabetic nephropathy.
Diabetes Care. 31:823–827. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Bhattacharya S, Mandal SK, Bandyopadhyay
R, Chakrabarti S, Basu AK and Pal S: A study on nephropathy in type
2 diabetes mellitus: Histology and its correlation with clinical
and biochemical parameters. J Indian Med Assoc. 105:592594–596.
2007.PubMed/NCBI
|
|
141
|
Taneda S, Pippin JW, Sage EH, Hudkins KL,
Takeuchi Y, Couser WG and Alpers CE: Amelioration of diabetic
nephropathy in SPARC-null mice. J Am Soc Nephrol. 14:968–980. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Reed MJ, Puolakkainen P, Lane TF,
Dickerson D, Bornstein P and Sage EH: Differential expression of
SPARC and thrombospondin 1 in wound repair: Immunolocalization and
in situ hybridization. J Histochem Cytochem. 41:1467–1477. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Dallinga MG, Yetkin-Arik B, Kayser RP,
Vogels IMC, Nowak-Sliwinska P, Griffioen AW, van Noorden CJF,
Klaassen I and Schlingemann RO: IGF2 and IGF1R identified as novel
tip cell genes in primary microvascular endothelial cell
monolayers. Angiogenesis. 21:823–836. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Wang Q, Wu G, Zhang Z, Tang Q, Zheng W,
Chen X, Chen F, Li Q and Che X: Long non-coding RNA HOTTIP promotes
renal cell carcinoma progression through the regulation of the
miR-615/IGF-2 pathway. Int J Oncol. 53:2278–2288. 2018.PubMed/NCBI
|
|
145
|
Qian SB, Li XY, Yu YJ, Wu Y, Shen HB, Xu D
and Qi J: Effect of targeted induction of IGF2 promoter hP4
methylation on imprinting status of renal cancer cells. Int J Urol
Nephrol. 39:1000–1004. 2019.(In Chinese).
|
|
146
|
Nonomura N, Nishimura K, Miki T, Kanno N,
Kojima Y, Yokoyama M and Okuyama A: Loss of imprinting of the
insulin-like growth factor II gene in renal cell carcinoma. Cancer
Res. 57:2575–2577. 1997.PubMed/NCBI
|
|
147
|
Oda H, Kume H, Shimizu Y, Inoue T and
Ishikawa T: Loss of imprinting of igf2 in renal-cell carcinomas.
Int J Cancer. 75:343–346. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Jiang A, Wu X, Wang D, Wang A, Dong K, Liu
B, Qu L, Luo P, Wang J, Tong Q and Wang L: A new thinking:
Deciphering the aberrance and clinical implication of IGF axis
regulation pattern in clear cell renal cell carcinoma. Front
Immunol. 13:9355952022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Steenman MJ, Rainier S, Dobry CJ, Grundy
P, Horon IL and Feinberg AP: Loss of imprinting of IGF2 is linked
to reduced expression and abnormal methylation of H19 in Wilms'
tumour. Nat Genet. 7:433–439. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Taniguchi T, Schofield AE, Scarlett JL,
Morison IM, Sullivan MJ and Reeve AE: Altered specificity of IGF2
promoter imprinting during fetal development and onset of Wilms
tumour. Oncogene. 11:751–756. 1995.PubMed/NCBI
|
|
151
|
Wegert J, Fischer AK, Palhazi B, Treger
TD, Hilgers C, Ziegler B, Jung H, Jüttner E, Waha A, Fuchs J, et
al: TRIM28 inactivation in epithelial nephroblastoma is frequent
and often associated with predisposing TRIM28 germline variants. J
Pathol. 262:10–21. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Haruta M, Arai Y, Watanabe N, Fujiwara Y,
Honda S, Ohshima J, Kasai F, Nakadate H, Horie H, Okita H, et al:
Different incidences of epigenetic but not genetic abnormalities
between Wilms tumors in japanese and caucasian children. Cancer
Sci. 103:1129–1135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Iams WT and Lovly CM: Molecular pathways:
Clinical applications and future direction of insulin-like growth
factor-1 receptor pathway blockade. Clin Cancer Res. 21:4270–4277.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Haluska P, Menefee M, Plimack ER,
Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang
J, et al: Phase I dose-escalation study of MEDI-573, a bispecific,
antiligand monoclonal antibody against IGFI and IGFII, in patients
with advanced solid tumors. Clin Cancer Res. 20:4747–4757. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Rihawi K, Ong M, Michalarea V, Bent L,
Buschke S, Bogenrieder T, Anthoney A, De Bono JS and Twelves C:
Phase I dose escalation study of 3-weekly BI 836845, a fully human,
affinity optimized, insulin-like growth factor (IGF) ligand
neutralizing antibody, in patients with advanced solid tumors. J
Clin Oncol. 32 (15 Suppl):S26222014. View Article : Google Scholar
|
|
156
|
Tian B, Zhao Y, Liang T, Ye X, Li Z, Yan
D, Fu Q and Li Y: Curcumin inhibits urothelial tumor development by
suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway.
J Drug Target. 25:626–636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Anderson PM, Bielack SS, Gorlick RG,
Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E,
Pápai Z, et al: A phase II study of clinical activity of SCH 717454
(robatumumab) in patients with relapsed osteosarcoma and ewing
sarcoma. Pediatr Blood Cancer. 63:1761–1770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Arango-Argoty G, Bikiel DE, Sun GJ,
Kipkogei E, Smith KM, Carrasco Pro S, Choe EY and Jacob E:
AI-driven predictive biomarker discovery with contrastive learning
to improve clinical trial outcomes. Cancer Cell. 43:875–890.e8.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun
K, Maw MA, Smith PJ and Reeve AE: Relaxation of insulin-like growth
factor II gene imprinting implicated in Wilms' tumour. Nature.
362:749–751. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Hu Q, Gao F, Tian W, Ruteshouser EC, Wang
Y, Lazar A, Stewart J, Strong LC, Behringer RR and Huff V: Wt1
ablation and Igf2 upregulation in mice result in Wilms tumors with
elevated ERK1/2 phosphorylation. J Clin Invest. 121:174–183. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Alders L, Pirlet E, Gesquiere E and
Bronckaers A: The role of IGF-2 and its variants in enhancing
endothelial migration and angiogenesis. Front Cell Dev Biol.
13:15987052025. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Yang Y and Yee D: Targeting insulin and
insulin-like growth factor signaling in breast cancer. J Mammary
Gland Biol Neoplasia. 17:251–261. 2012. View Article : Google Scholar : PubMed/NCBI
|
